BioRestorative Therapies to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025

Core Insights - BioRestorative Therapies, Inc. will release its third quarter 2025 financial results on November 12, 2025, after market close, followed by a conference call for a business update [1][2] Company Overview - BioRestorative is focused on regenerative medicine, particularly stem cell-based therapies and products [3] - The company has two main clinical development programs: the Disc/Spine Program and the Metabolic Program, along with a commercial BioCosmeceutical platform [3][4] Disc/Spine Program - The lead cell therapy candidate, BRTX-100, is derived from a patient's own cultured mesenchymal stem cells and is intended for non-surgical treatment of lumbosacral disc disorders [3] - BRTX-100 is currently in a Phase 2 clinical trial for chronic lower back pain due to degenerative disc disease and has received FDA IND clearance for chronic cervical discogenic pain [3] Metabolic Program - The ThermoStem® program aims to develop therapies targeting obesity and metabolic disorders using brown adipose-derived stem cells (BADSC) [4] - Initial preclinical research suggests that increased brown fat may enhance caloric burning and lower glucose and lipid levels, potentially reducing obesity and diabetes risk [4] BioCosmeceuticals - The company operates a commercial BioCosmeceutical platform, offering a cell-based secretome product designed to reduce fine lines and wrinkles [5] - Future plans include expanding the product line to include more cell-based aesthetic products and therapeutics, with the goal of obtaining FDA approvals [5]